Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

NCT03244072 Phase 2/Phase 3 NOT_YET_RECRUITING

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Details

Lead sponsor	Jason Ahee, M.D.
Phase	Phase 2/Phase 3
Status	NOT_YET_RECRUITING
Enrolment	60000
Start date	2026-06-01
Completion	2031-10

Conditions

• Endophthalmitis

Interventions

• Moxifloxacin
• Placebo

Primary outcomes

• Endophthalmitis after cataract surgery — Subjects will undergo eye examinations at one day, one week, and one month post-operatively
  Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.

Countries

United States